RT Journal Article
SR Electronic
T1 Early diagnosis of coeliac disease in the Preventive Youth Health Care Centres in the Netherlands: study protocol of a case-finding study (GLUTENSCREEN)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.24.21254842
DO 10.1101/2021.04.24.21254842
A1 Meijer, Caroline R.
A1 van den Akker, M. Elske
A1 van Bodegom, Leti
A1 Escher, Johanna C.
A1 van Geloven, Nan
A1 van Overveld, Floris
A1 Rings, Edmond H.H.M.
A1 Smit, Lucy
A1 de Vries, Martine
A1 Mearin, M. Luisa
YR 2021
UL http://medrxiv.org/content/early/2021/04/26/2021.04.24.21254842.abstract
AB Introduction Coeliac disease (CD) occurs in 1% of the population, develops early in life and is severely underdiagnosed. Undiagnosed and untreated disease is associated with short- and long-term complications. Treatment with a gluten-free diet results in health improvement. The current health care approach is unable to solve the underdiagnosis of CD and timely diagnosis and treatment is only achieved by active case finding. Aim of this study is to perform a novel case-finding project to detect CD in 12 months-4 years old symptomatic children who visit the YHCCs in a well-described region in the Netherlands to show that it is feasible, cost-effective and well accepted by the population.Methods/analysis Prospective intervention cohort study. Parents of all children aged 12 months-4 years attending the Youth Health Care Centres (YHCCs) for a regular visit are asked if their child has one or more CD-related symptoms from a standardized list. If so, they will be invited to participate in the case-finding study. After informed consent, a point of care test (POC) to assess CD-specific antibodies against tissue-transglutaminase (TG2A) from a droplet of blood, is performed onsite at the YHCCs. If the POC test is positive, CD is highly suspected and the child will be referred to hospital for definitive diagnosis according to the ESPGHAN guideline.Main outcomes: 1. incidence rate of new CD diagnoses in the study region Kennemerland in comparison to the rest of the Netherlands.2. Feasibility and cost-effectiveness of active case-finding for CD in the YHCCs. All costs of active case finding, diagnostics and treatment of CD and the potential short and long term consequences of the disease will be calculated for the setting with and without case finding.3. Ethical acceptability: by questionnaires on parental and health care professionals satisfaction. A statistical analysis plan (SAP) has been written and will be published on the GLUTENSCREEN website.Ethics and dissemination The Medical Ethics Committee Leiden approved this study. If we prove that active case finding in the YHCC is feasible, efficient, cost-effective and well accepted by the population, implementation is recommended.Trial registration number NL63291.058.17What is already known on this topic?Despite recommendation on ‘who should be tested for CD’ in guidelines, the diagnosis of CD remains severely underdiagnosed.Untreated CD has a considerable health burden for society.Studies have shown that an active case-finding strategy in adults is an effective means to improve the frequency of CD diagnosis.What this study hopes to add?Effectiveness and feasibility of active-case finding as secondary prevention strategy in the diagnosis of childhood CD in the primary care setting in the NetherlandsThis study will provide important information about the cost-effectiveness and acceptability of the general Dutch population concerning active case-findingCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNL63291.058.17Funding StatementThis work is supported by ZonMW, grant number 531002001 and Biohit Oyj Headquarters.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Medical Ethics Committee of the Leiden University Medical Centre.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Management Plan for this study is available.CDCeliac diseaseCME-LUMCMedical Ethics Committee of the Leiden University Medical CentreDPSUDutch Pediatric Surveillance Unit. In Dutch: Nederlands Signalerings Centrum Kindergeneeskunde, NSCKEMAEndomysium antibodiesESPGHANEuropean Society for Pediatric Gastroenterology Hepatology and NutritionGFDgluten free dietHLAhuman leucocyte antigenIgAimmunoglobulin ALUMCLeiden University Medical CentreMETC-LDDMedical Ethics Committee- Leiden Den Haag DelftNCVDutch Coeliac SocietyPOCpoint of contactTG2AAnti-tissue transglutaminase antibodiesYHCCYouth Health Care Centres